Suppr超能文献

慢性阻塞性肺疾病和骨质疏松症患者的处方模式。

Prescription Patterns in Patients with Chronic Obstructive Pulmonary Disease and Osteoporosis.

机构信息

Department of Internal Medicine, Chi Mei Medical Center, Chiali, Taiwan, Republic of China.

Master Program in Clinical Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.

出版信息

Int J Chron Obstruct Pulmon Dis. 2021 Mar 25;16:761-769. doi: 10.2147/COPD.S289799. eCollection 2021.

Abstract

OBJECTIVE

Patients with chronic obstructive pulmonary disease (COPD) have a higher risk of osteoporosis. Few studies have addressed the prescription patterns in osteoporosis patients with COPD. The purpose of this study was to conduct a retrospective study of the prescription patterns in patients with COPD and osteoporosis in Taiwan.

METHODS

The study was conducted with data from the Taiwan National Health Insurance Research Database from January 1, 2003, to December 31, 2016. We selected the COPD population in Taiwan older than 40 years with at least one prescription for a bronchodilator. We excluded patients who had osteoporosis, fracture, asthma, or cancer before the diagnosis of COPD. After the diagnosis of COPD, patients who did not have osteoporosis were also excluded. We followed this COPD and osteoporosis cohort until they had been prescribed medication for osteoporosis.

RESULTS

There were 13,407 patients with COPD and osteoporosis who received osteoporosis treatment. Among the patients who received treatment, the majority were female (n = 9136), accounting for 68.14% of all treated patients. A total of 53.4% of the patients had been prescribed steroids least once within the last year before receiving a diagnosis of osteoporosis. A total of 34.61% of the patients received systemic corticosteroids with a daily dose equivalent to 5 mg of prednisolone within the 3 months prior to the diagnosis of osteoporosis. The older the patient was, the higher the probability of the prescription of medication for osteoporosis. Patients with depression had a high probability of receiving medication for osteoporosis with adjusted hazard ratio of 1.141 (95% confidence interval, 1.072-1.214).

CONCLUSION

The rate of prescriptions for the treatment of osteoporosis in patients with COPD was low. Physicians need to be aware of this issue and treat osteoporosis more aggressively in patients with COPD.

摘要

目的

慢性阻塞性肺疾病(COPD)患者发生骨质疏松的风险较高。鲜有研究探讨 COPD 合并骨质疏松患者的处方模式。本研究旨在对台湾地区 COPD 合并骨质疏松患者的处方模式进行回顾性研究。

方法

本研究使用了台湾全民健康保险研究数据库 2003 年 1 月 1 日至 2016 年 12 月 31 日的数据。我们选择了年龄在 40 岁以上、至少有一次支气管扩张剂处方的台湾 COPD 人群。排除骨质疏松症、骨折、哮喘或癌症诊断前患有 COPD 的患者。在 COPD 诊断后,没有骨质疏松症的患者也被排除在外。我们对 COPD 和骨质疏松症队列进行随访,直到他们开始接受骨质疏松症治疗。

结果

共有 13407 名患有 COPD 和骨质疏松症的患者接受了骨质疏松症治疗。在接受治疗的患者中,大多数为女性(n=9136),占所有接受治疗患者的 68.14%。在诊断骨质疏松症前的过去 1 年中,有 53.4%的患者至少接受过一次激素治疗。在诊断骨质疏松症前的 3 个月内,有 34.61%的患者接受了相当于 5mg 泼尼松龙剂量的全身皮质类固醇治疗。患者年龄越大,处方骨质疏松症治疗药物的可能性越高。患有抑郁症的患者接受骨质疏松症治疗药物的可能性较高,调整后的危险比为 1.141(95%置信区间,1.072-1.214)。

结论

COPD 患者治疗骨质疏松症的处方率较低。医生需要意识到这一问题,并更积极地治疗 COPD 患者的骨质疏松症。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fa4/8007556/05839f1d0702/COPD-16-761-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验